Affimed Wins FDA Fast Track Designation for AFM13 in Combination with AlloNK for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Affimed N.V. (NASDAQ:AFMD) has been granted fast track designation by the FDA for its combination treatment of AFM13 with AlloNK for the potential treatment of relapsed/refractory Hodgkin lymphoma. The treatment is entering Phase 2 development and will be investigated in Affimed's LuminICE-203 study.
September 12, 2023 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Affimed N.V. has received FDA fast track designation for its AFM13 and AlloNK combination treatment for Hodgkin lymphoma, which is entering Phase 2 development.
The FDA fast track designation is a significant regulatory milestone that could accelerate the development and review of Affimed's treatment. This could potentially lead to earlier revenue generation from the treatment, which is positive for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100